Menachem Rubinstein

Prof. Menachem Rubinstein

orcid

Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
DFDanit Finkelshtein
Danit Finkelshtein
AWAriel Werman
Ariel Werman
DNDaniela Novick
Daniela Novick
SBSara Barak
Sara Barak
MRMenachem Rubinstein
Menachem Rubinstein
Vesicular stomatitis virus (VSV) exhibits a remarkably robust and pantropic infectivity, mediated by its coat protein, VSV-G. Using this property, recombinant forms of VSV and VSV-G-pseudotyped viral vectors are being developed for gene therapy, vaccination, and viral oncolysis and are extensively used for gene transduction in vivo and in vitro. The broad tropism of VSV suggests that it enters cells through a highly ubiquitous receptor, whose identity has so far remained elusive. Here we show that the LDL receptor (LDLR) serves as the major entry port of VSV and of VSV-G-pseudotyped lentiviral vectors in human and mouse cells, whereas other LDLR family members serve as alternative receptors. The widespread expression of LDLR family members accounts for the pantropism of VSV and for the broad applicability of VSV-G-pseudotyped viral vectors for gene transduction.

1 January 1999 in Immunity
Verified
Journal Article
Closed access
DNDaniela Novick
Daniela Novick
SKSoo-Hyun Kim
Soo-Hyun Kim
GFGiamila Fantuzzi
Giamila Fantuzzi
LRLeonid L Reznikov
Leonid L Reznikov
CDCharles A Dinarello
Charles A Dinarello
MRMenachem Rubinstein
Menachem Rubinstein

9 September 2007 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
ASAsaf Spiegel
Asaf Spiegel
SSShoham Shivtiel
Shoham Shivtiel
AKAlexander Kalinkovich
Alexander Kalinkovich
ALAya Ludin
Aya Ludin
NNNeta Netzer
Neta Netzer
TLTsvee Lapidot
Tsvee Lapidot

1 February 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SKSoo-Hyun Kim
Soo-Hyun Kim
MEMiriam Eisenstein
Miriam Eisenstein
LRLeonid Reznikov
Leonid Reznikov
GFGiamila Fantuzzi
Giamila Fantuzzi
DNDaniela Novick
Daniela Novick
CDCharles A. Dinarello
Charles A. Dinarello
A novel, constitutively expressed and secreted IL-18 binding protein (IL-18BP) neutralizes IL-18 and thereby suppresses the production of IFN-γ, resulting in reduced T-helper type 1 immune responses. In the present study, four human and two mouse isoforms, resulting from mRNA splicing and found in various cDNA libraries, were expressed, purified, and assessed for binding and neutralization of IL-18 biological activities. Human IL-18BP isoform a (IL-18BPa) exhibited the greatest affinity for IL-18 with a rapid on-rate, a slow off-rate, and a dissociation constant (Kd) of 399 pM. IL-18BPc shares the Ig domain of IL-18BPa except for the 29 C-terminal amino acids; theKdof IL-18BPc is 10-fold less (2.94 nM). Nevertheless, IL-18BPa and IL-18BPc neutralize IL-18 >95% at a molar excess of two. IL-18BPb and IL-18BPd isoforms lack a complete Ig domain and lack the ability to bind or neutralize IL-18. Murine IL-18BPc and IL-18BPd isoforms, possessing the identical Ig domain, also neutralize >95% murine IL-18 at a molar excess of two. However, murine IL-18BPd, which shares a common C-terminal motif with human IL-18BPa, also neutralizes human IL-18. Molecular modeling identified a large mixed electrostatic and hydrophobic binding site in the Ig domain of IL-18BP, which could account for its high affinity binding to the ligand. It is likely that preferential secretion of functional and nonfunctional isoforms of IL-18BP affect the immune response.

18 January 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
FVFernando Vidal-Vanaclocha
Fernando Vidal-Vanaclocha
GFGiamila Fantuzzi
Giamila Fantuzzi
LMLorea Mendoza
Lorea Mendoza
AFAngela M. Fuentes
Angela M. Fuentes
MAMiren J. Anasagasti
Miren J. Anasagasti
CDCharles A. Dinarello
Charles A. Dinarello
Proinflammatory cytokines, including IL-1βand tumor necrosis factor-α(TNF-α), promote cancer cell adhesion and liver metastases by up-regulating the expression of vascular cell adhesion molecule-1 (VCAM-1) on hepatic sinusoidal endothelium (HSE). In this study, hepatic metastasis after intrasplenically injected mouse B16 melanoma (B16M) cells was reduced 84–95% in mice with null mutations for either IL-1βor the IL-1β-converting enzyme (ICE, caspase-1) compared with wild-type mice. On day 12, 47% of wild-type mice were dead compared with 19% of either IL-1βor ICE-deficient mice.In vitro, conditioned medium from B16M cells (B16M-CM) induced the release of TNF-αand IL-1βfrom cultures of primary murine HSE. The effect of B16M-CM on HSE resulted in increased numbers of B16M cells adhering to HSE, which was completely abrogated by a specific inhibitor of ICE, anti-IL-18 or IL-18-binding protein. Exogenous IL-18 added to HSE also increased the number of adhering melanoma cells; however, this was not affected by IL-1 receptor blockade or TNF neutralization but rather by anti-VCAM-1. These results demonstrate a role for IL-1βand IL-18 in the development of hepatic metastases of B16Min vivo.In vitro, soluble products from B16M cells stimulate HSE to sequentially release TNF-α, IL-1β, and IL-18. The IL-18 cytokine increases expression of VCAM-1 and the adherence of melanoma cells.

1 May 1982 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MFM Fellous
M Fellous
UNU Nir
U Nir
DWD Wallach
D Wallach
GMG Merlin
G Merlin
MRMenachem Rubinstein
Menachem Rubinstein
MRM Revel
M Revel
In human cells treated with interferons, there is an increase in the amount of HLA-A,B,C and beta 2-microglobulin exposed on the cell surface. We have used a cloned HLA-A,B,C cDNA probe to demonstrate by molecular hybridization that this effect of interferon is preceded by a large increase in the amount of HLA mRNA in the cell. This effect was found in five different human cell lines, with purified leukocyte and fibroblast interferons. The increase in HLA mRNA is comparable in its kinetics and dose-response to the induction of (2'-5') oligo(A) synthetase mRNA by interferons. Therefore, interferons seem to activate at least two cellular genes which have different biochemical functions.